The industry downturn caused by the pandemic has prompted the group to embark on a long-overdue cost-restructuring program that will lead to a leaner cost structure.
The ELDERCARE‐AF trial showed that low‐dose edoxaban benefits elderly patients with nonvalvular atrial fibrillation considered ineligible for standard oral anticoagulants due to high bleeding risk, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results